ZMYM2

Across TCGA pan-cancer cohorts, ZMYM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZMYM2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZMYM2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZMYM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, COAD, and CCRCC are the cancer types where ZMYM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.731	0.921	.010	47	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	4	view →
LSCC	OS	Median	II,III,IV	0.839	0.601	.026	3	view →
PDAC	DFS	Median	II,III,IV	0.329	0.488	.042	2	view →
GBM	OS	Quartile	All	0.540	0.338	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZMYM2–HNSC (OS)

Open the HNSC breakdown →